To test the cytotoxicity and specificity of established CD19-NK-92 and CD138-NK-92 cells, we first assessed the expression of CD19 and CD138 surface antigens in various hematologic cancer cell lines to identify representative target cells with differential CD19 and CD138 expression profiles. Here, CD19 is linked to hematopoietic and lymphoid cell neoplasm.